Dr. Reddy's Laboratories Ltd has posted results for the first quarter ended 30th June, 2012.

Its net profit was stood at Rs3.36bn.

The company also reported revenue of Rs 25.40bn.

Global Generics
Revenues from Global Generics segment at Rs19.1 bn in Q1 FY13,year-on-year growth of 32% driven by key markets of North America, Russia & other emerging markets.

Revenues from North America at Rs7.9 billion in Q1 FY13grew by 27% in USD terms, over previous year.
Growth was largely driven by new product launches of clopidogrel, OTC lansoprazoleand was further supported by key products of ziprasidone, fondaparinux, quetiapine,etc, marginally offset by regular year-on-year price declines in existing product basket.
5 new products were launched during the quarter including clopidogrel 300 Mg which was launched under 180-day exclusivity.
29 products of prescription portfolio feature among the Top 3 ranks in market shares  (Source: IMS Health Volumes April 2012).
During the quarter, 4 ANDAs were filed. Cumulatively 73 ANDAs are pending for approval with the USFDA of which 36 are Para IVs and 6are with FTF status.

Revenues in Russia and Other CIS markets at Rs4.2 bn in Q1 FY13represented year-on-year growth of 38%.
Revenues in Russia at Rs3.5 billion in Q1 FY13was the highest ever from this market and represented year-on-year growth of 30% in Rouble terms.
Growth was driven by new product launches, volume increase across key brands and OTC portfolio.
Revenues in Other CIS markets at Rs0.65billion in Q1 FY13 grew by 22% over previous year.

Revenues in India at Rs3.5 billion in Q1FY13 grew by 19% over previous year.
Growth driven by volume increase across most of our key brands.
Biosimilars portfolio grew by 15% over previous year.
10 new brands were launched during the quarter.

Revenues from Europe at Rs2.2 billion in Q1 FY13 grew by 14% over previous year.
Revenues from Germanyat Rs1.5 billion in Q1 FY13grew by 17% in Euro termsover previous year. This growth was largely due to the products supplied under the AOK tender won last year.

Pharmaceutical Services and Active Ingredients (PSAI)
Revenues from PSAI are at Rs5.5 billion in Q1 FY 13, year-on-year growth of 14%.
During the quarter, 7 DMFswere filed globally, with 1each in the US and Europe. The cumulative DMF filings as of 30th June 2012 are 550.

Hero MotoCorp Q1 net profit at Rs. 6.15bn